Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 86   

Articles published

ARNA 1.52 +0.05 (3.40%)
price chart
Arena Pharmaceuticals Incorporated (NASDAQ:ARNA) Shorted Shares Increased By 0.25%
The short interest to Arena Pharmaceuticals Incorporated's float is 8.85%. The stock is down 1.36% or $0.02 after the news, hitting $1.45 per share.
Here's Why Arena Pharmaceuticals, Inc. Is Struggling Today
What: Arena Pharmaceuticals (NASDAQ:ARNA) was down as much as 12% today after its marketing partner Eisai released financial results for the first half of its fiscal year.
Needham Reiterates Hold on Arena Pharmaceuticals, Inc. (ARNA) Ahead of Earnings  Smarter Analyst
What The Future Holds For Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)'s?
In today's trading session, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)'s stock opened at 1.48 and was trading at 1.48 at the time of writing.
Why Arena Pharmaceuticals, Inc. Bulked Up in November
Shares of Arena Pharmaceuticals (NASDAQ:ARNA), a drug developer focused on a variety of ailments including weight control management, vascular diseases, and autoimmune diseases, surged higher by 26% in November, according to data from S&P ...
Biotech Beach: Needham Provides Updates on Gilead Sciences, Inc. (GILD), Arena ...
The biotechnology sector is always volatile, and the recent market sell-off only makes it more so. Consequently, Alan Carr of Needham notes that it is best to focus on “commercial-stage or regulatory-stage companies with substantial cash reserves” at ...
Price Target Update On Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
A number of investment brokers have recently updated their price targets on shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA).
Arena Pharmaceuticals Inc. (ARNA) Jumps 9.66% on February 04
Arena Pharmaceuticals Inc. (ARNA) was among the biggest gainers on the Russell 2000 for Thursday February 04 as the stock popped 9.66% to $1.59, representing a gain of $0.14 per share.
Arena Pharmaceuticals: A Lack Of Clarity Heading Into 2016
Yes, Arena does have a large pharmaceutical partner in Eisai helping to market the drug, but the question is how much more in terms of marketing and sales resources is Eisai willing to continue devoting towards this product?
Arena Pharmaceuticals to lay off 35 percent of US workers  Reuters
Arena Pharmaceuticals Initiates a Phase 1b Clinical Trial of APD371  PR Newswire (press release)
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) PT & Analyst Recommendation Review
Brokerage firms monitoring company shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) have placed a $3.75 price target on the stock in the short term.
Analyst Review Alert: Arena Pharmaceuticals, Inc. (ARNA)  CWRU Observer
Arena Pharmaceuticals, Inc. (ARNA) Earns Hold Rating from Needham & Company LLC
Needham & Company LLC reiterated their hold rating on shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) in a research note issued to investors on Wednesday, MarketBeat Ratings reports.